An accurate assessment of iron status in dialysis patients is important because both anemia and overtreatment with erythropoiesis-stimulating agents are associated with poor clinical outcomes. We have previously shown that both analytical and intra-individual (biological) variability in serum ferritin limits its utility as a proxy for iron stores in patients in this setting. As hepcidin is a direct regulator of iron status, its measurement might be useful for monitoring patients with iron dysregulation. We assessed short-term intra-individual variation of serum hepcidin in 28 patients with stable chronic kidney disease on hemodialysis. The intra-individual variability for serum hepcidin ranged from 9-79% during an initial 2-week to 12-85% over a 6-week period. The concentration of serum hepcidin was significantly correlated with serum C-reactive protein levels over the 6-week study period. Hence, significant intra-individual variability of hepcidin is likely dependent on short-term fluctuations in the inflammatory state. Thus, our results suggest that short-term measurement of serum hepcidin should not be used to guide clinical decisions regarding management of iron status in chronic hemodialysis patients.
Patients on chronic hemodialysis should undergo laboratory assessment of their hematological and iron status at least every 3 months according to the 2006 National Kidney Foundation KDOQI (Kidney Disease Outcomes Quality Initiative) Guidelines and Clinical Practice Recommendations. 1 At present, this assessment includes measurement of serum ferritin and transferrin saturation. An accurate assessment of iron status is important because both anemia 2 and overtreatment with erythropoiesis-stimulating agents [3] [4] [5] are associated with poor clinical outcomes.
We have previously shown that both analytical and intraindividual (biological) variability in serum ferritin limits its utility as a proxy for iron stores in patients with chronic kidney disease (CKD) on hemodialysis. 6 Ferritin is an acutephase reactant that may not correlate with iron status in chronic disease states, such as CKD. 7 This has led to a search for better markers of iron status in CKD patients on hemodialysis, with serum hepcidin emerging as a promising candidate. 8, 9 Hepcidin was originally described as an antimicrobial peptide produced by the liver but its main biological role seems to be iron homeostasis. It suppresses iron absorption from the intestine and stimulates iron retention in cells expressing ferroportin, notably macrophages and hepatocytes. 10 Owing to its role as a direct regulator of iron status, measurement of serum hepcidin is conceptually attractive in patients with iron dysregulation. Ganz et al. 11 recently validated an immunoassay for serum hepcidin-25 by establishing reference intervals in healthy volunteers, determining its analytical performance, and demonstrating that serum hepcidin was low in patients with iron deficiency anemia and high in classical hereditary hemochromatosis. The primary objective of this study was to use this new assay to assess intra-individual variability in serum hepcidin concentrations in stable CKD patients on chronic hemodialysis over a total of 6 weeks and compare it with that of serum ferritin. A secondary objective was to compare the variability in serum C-reactive protein (CRP) with that of serum hepcidin and ferritin to estimate the degree to which inflammatory status may influence the concentration of these two analytes.
RESULTS

Intra-individual variability of serum hepcidin and serum ferritin
The characteristics and baseline laboratory results of the 28 patients are summarized in Table 1 . Both gender and race distributions are consistent with patient demographics in our urban hemodialysis centers. The median intra-individual coefficient of variability (CV I ) of serum hepcidin over 2 weeks (n ¼ 4 samples per subject) was 19.0% (interquartile range (IQR): 13.0, 25.2%) ( Table 2 ). For the 6-week period (n ¼ 8 samples per subject), the median CV I for serum hepcidin was 22.9% (IQR: 18.0, 39.7%). In comparison, the median CV I of serum ferritin for these 28 patients over the 2-week period was 8.6% (IQR: 5.2, 13.7%). For the 6-week period, the median CV I of serum ferritin was 11.5% (IQR: 7.3, 17.8%). CV I s of serum hepcidin and ferritin were uncorrelated over either the 2-or the 6-week period, and the serum hepcidin CV I s for the three groups of patients stratified by initial serum ferritin were not different over 6 weeks (P ¼ 0.32, analysis of variance).
There was a wide variation in the correlation of these markers within subjects ( Figure 1 ). There was a statistically significant (Po0.05) within-subject correlation between serum hepcidin and ferritin in 5 of the 28 patients. Of these, four exhibited a positive correlation and one exhibited a negative correlation (Figures 1 and 2a ). All others showed no statistically significant correlation between ferritin and hepcidin concentrations with several examples shown in Figure 2b . Within-individual correlation of hepcidin with CRP and ferritin with CRP was also widely variable with correlations reaching significance in only four and six subjects, respectively ( Figure 1 ). Comparing all ferritin-hep- cidin sample pairs as a group rather than within individuals, serum ferritin and hepcidin were correlated (r ¼ 0.57, Po0.01, Figure 3a ). Hepcidin and CRP were correlated (Figure 3b ), whereas ferritin and CRP were not significantly correlated ( Figure 3c ). Among other measures related to iron status, the average epoetin dose per week was negatively correlated with transferrin saturation at mid-study (3 weeks; r ¼ À0.46, P ¼ 0.01) and negatively correlated with the average iron dose per week (r ¼ À0.42, P ¼ 0.03). However, the average epoetin dose was not correlated with the change in serum hepcidin over the course of the study (Figure 3d ). In addition, average epoetin dose did not correlate with baseline hepcidin or average hepcidin over 6 weeks. Mean serum hepcidin was not significantly correlated with either mean transferrin saturation (r ¼ 0.21, P ¼ 0.28) or mean weekly iron dose (r ¼ 0.08, P ¼ 0.70).
Correlation of serum hepcidin, ferritin, and CRP intra-individual variability CV I s for serum hepcidin over 2 and 6 weeks had modest positive correlations with CV I s for CRP over 6 weeks (r ¼ 0.42 and r ¼ 0.43; P ¼ 0.03 and P ¼ 0.02, respectively). Serum ferritin over 2 and 6 weeks was not significantly 
DISCUSSION
This study demonstrates large intra-individual variability in serum hepcidin over 2-and 6-week periods that appears to be similar to that observed for serum ferritin, which is a more commonly used, but imperfect, indicator of iron status in CKD patients on hemodialysis. As we selected patients for stable clinical status and consistent iron and epoetin dosing, 6 the intra-individual variability among all dialysis patients is likely to be even higher for both serum hepcidin and ferritin. Clinically significant changes in laboratory measurements can be defined by the reference change value or critical difference, 12 which encompasses both intra-individual variation (CV I ) and analytical variation (CV A ). For 95% confidence that a physiological change has occurred, the reference change value is calculated as 2.77 Â (CV A 2 þ CV I 2 ) 0.5 . Assuming a CV A of 7% 11 and the biological variability (CV I ) listed in Table 2 , the critical difference is 56 and 66% over the 2-and 6-week periods, respectively, using the median CV I s for serum hepcidin. Considering the mean serum hepcidin of 553 ng/ml (similar to the median serum hepcidin 652 ng/ml as observed by Zaritsky et al. 13 in a pediatric population on hemodialysis) a physiological change in our study population would be defined as ±365 ng/ml over 6 weeks. As we have previously described for ferritin, 6 this likely limits the clinical utility of hepcidin as an indicator of iron stores and of shortterm changes in iron status in CKD patients on hemodialysis.
Ashby et al. 14 showed a decrease of B20 ng/ml in serum hepcidin in six healthy subjects administered recombinant human erythropoietin. There may be several reasons why we did not see a correlation between epoetin dose and serum hepcidin. The many differences in physiology between healthy subjects and our patient population, leading to the high intra-individual variability seen herein, may mask a statistically significant correlation if the magnitude of the epoetin effect is on the order of that observed by Ashby et al. Alternately, it may be that iron metabolism is sufficiently dysregulated in patients on chronic hemodialysis that there is no correlation; a large interventional trial would be better suited to explore this possibility.
Some of the larger intra-individual variations in serum hepcidin relative to serum ferritin observed in this study may be due to a larger dependence of serum hepcidin on shortterm changes in the inflammatory state, as suggested by the modest correlation between serum hepcidin and CRP and the lack of any correlation between serum ferritin and CRP. Ganz et al., using the assay in this study, found a positive correlation between serum hepcidin and ferritin in healthy subjects, as well as a correlation between serum hepcidin and elevated CRP. 11 The fact that serum hepcidin is closely tied to systemic inflammation may limit its use as a proxy for iron status in CKD patients, who often exhibit chronic inflamma-tion. The large intra-individual variability in CRP observed in this population (CV I ¼ 45.5% over 2 weeks and CV I ¼ 53% over 6 weeks) is very similar to that measured in a similarsized population of healthy subjects (26 normal subjects, CV I ¼ 42.2% 15 ), suggesting that we have successfully selected a similarly stable population of patients. We expect that in a population not selected for clinical stability and in which blood draws are performed with less attention to the timing of iron administration, both the CV I s for serum hepcidin and ferritin might be even greater. [16] [17] [18] It is clear that serum hepcidin reflects both iron status and inflammation, making it difficult to interpret strictly in terms of iron status.
Most of the hepcidin assays that have been produced to date are not applicable to an anuric population as they assay urine hepcidin. 19, 20 Other assays are semi-quantitative 21 or require complicated procedures unlikely to be practical in common clinical laboratory settings. 22 However, among assays for mature hepcidin, there is agreement between methods of measurement of urine and serum hepcidin, 23, 24 and most assays show analytical CVs similar to the assay used in this study. [25] [26] [27] 11 Furthermore, different assays show a similar association with CRP 28,29 that was recently duplicated by Zaritsky et al. 30 in patients on hemodialysis despite withholding parenteral iron for 1 week before hepcidin measurement. Given these findings, we do not expect that the lack of standardization among mature hepcidin assays to substantially affect our findings. A potential limitation might be that the assay used in this study detects forms of hepcidin other than hepcidin-25, which may be both physiologically inactive and present in high concentrations in patients on hemodialysis. Although this potential effect is uncharacterized in this case, Ashby et al. 14 reported that a polyclonal antibody produced identically to that used in this assay 11 had o10% cross-reactivity with species of hepcidin other than hepcidin-25, similar to that seen in healthy controls.
In conclusion, we have shown using a validated serum hepcidin assay that serum hepcidin exhibits both a high CV I and also correlates with CRP in stable patients with CKD on hemodialysis. These findings indicate that mature serum hepcidin may not provide an advantage over ferritin as a useful indicator of iron status in this patient population.
MATERIALS AND METHODS Study design
This study was approved by the Human Studies Committee at the Washington University as a subset of a previous study. 6 Additional informed consent to use previously collected patient specimens was obtained. The study consisted of determination of intra-individual variability in serum hepcidin and serum CRP concentration over 2 and 6 weeks in stable chronic hemodialysis patients. Ferritin values were obtained in samples after one freeze-thaw cycle in the previous study. 6 Overall, 9-10 patients from each of the three study groups from the previous study were selected (high, intermediate, and low initial serum ferritin groups) for further serum hepcidin analysis. Samples underwent a total of two freeze-thaw cycles before hepcidin measurement. Serum hepcidin has previously been shown to be stable through at least 6 months of storage and one freeze-thaw cycle in the assay used in this study, 11 and is stable through two freeze-thaw cycles (T Ganz, personal communication, unpublished data) in this assay and at least four freeze-thaw cycles in a mass spectroscopic method. 23 Samples were obtained twice a week for 2 weeks and then once a week for the next 4 weeks for a total of eight samples from each patient. Patients were 418 years of age, not pregnant, and on chronic hemodialysis three times per week, had missed no more than one hemodialysis session in the last 4 weeks, and had a baseline hemoglobin 410 g/100 ml. Patients were receiving either no iron or maintenance iron intravenously (defined as p125 mg per week of ferric gluconate or iron sucrose) for the previous 4 weeks. None had a change in iron dosing over the course of the study. No patients were receiving oral iron. All patients were receiving epoetin alfa (Epogen; Amgen; Thousand Oaks, CA, USA).
One patient had a single ferritin concentration of 8710 ng/ml in the fourth week that was confirmed three times and excluded from data analysis as an outlier; no other values were identified as outliers. Patient 11 did not have a sixth-week hepcidin sample, and patient 16 did not have a final poststudy hemoglobin sample drawn because of receipt of a kidney transplant; statistics were calculated without these values.
Exclusion criteria were active bleeding in the previous 8 weeks, transfusion within the last 12 weeks, any hematological disorder other than anemia, cancer, Gaucher's disease, acute or chronic liver disease, HIV (human immunodeficiency virus)-positive status, a history of autoimmune disease, antibiotics in the last month, or enrollment in another study.
Overall, 10 patients had initial ferritin 200-500 ng/ml; 9 patients had ferritin 500-800 ng/ml; and 9 had ferritin 800-1200 ng/ml. Blood was obtained immediately before administration of intravenous iron to minimize the contribution of intravenous iron to short-term intra-individual variability in serum iron indices. Samples were processed within 1 h of drawing and stored at À80 1C Serum hepcidin testing was performed on a fee for service basis at Intrinsic Life Sciences (La Jolla, CA, USA), which uses the assay described by Ganz et al. 11 This assay is a competitive enzymelinked immunosorbent assay for hepcidin-25 that has a published median analytical CV of 7%. All samples from any one patient were performed in the same run.
Statistical analysis
Short-term intra-individual variability in serum hepcidin and ferritin was summarized as CV I and IQRs. Day-to-day (over 2 weeks) and week-to-week (over 6 weeks) CV I s were calculated for each volunteer, as well as the mean, median, and range of CV I s for serum hepcidin and ferritin. Correlation coefficients were used to assess associations between variables, and outliers were excluded according to the method of Hadi. 31 A P-value o0.05 was considered significant. All calculations were performed using SYSTAT 12 (Systat, Chicago, IL, USA).
